Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025

Reuters

Oct 13

Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025

Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2575844383"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575844383\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575844383?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575844383","market":"fut","top_or_hot":-1,"title":"Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-13 06:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251012:nNDL1yqC1m:1","article_id":"2575844383","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575844383","pubTimestamp":1760306724,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology  Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗","BK4139":"生物科技"},"translate_title":"Incyte在ESMO 2025上宣布KRAS G12D抑制剂和TGF β R2xPD1双特异性抗体的积极1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    \n\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}